SOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)

Ciruelos, E. M.Gonzalez-Farre, X.Perello, A.Alba, E.Palacios-Ozores, P.Salvador-Bofil, J.Merino, M.Villagrasa, P.Celiz, P.Pascual, T.Prat, A.Pernas Simon, S.2025-01-072025-01-072020-05-010923-7534https://hdl.handle.net/10668/27095enSOLTI-1710 PROMETEO II: Palbociclib in combination with letrozole in patients with hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)conference outputopen access10.1016/j.annonc.2020.03.2151569-8041http://www.annalsofoncology.org/article/S0923753420362943/pdf538879300099